Recurring Features
The fixtures you can count on — every Monday, every month, every quarter. The cadence that keeps you ahead, on a schedule you can plan around.
The Monday Brief — Week of Aug 02, 2026
Galderma surges on GLP-1 tailwinds, AbbVie tightens margins, Nabota goes global—and 'Ozempic face' is reshaping your patient pipeline.
WeeklyThe Monday Brief — Week of Jul 26, 2026
Galderma's record H1 surge reshapes the market; Allergan's Boey lands in Europe; and the GLP-1 effect keeps driving demand.
WeeklyThe Monday Brief — Week of Jul 19, 2026
InMode faces competing takeover bids as Allergan wins EU approval for Boey; RF platforms accelerate; GLP-1 aesthetics market surges toward $2B.
WeeklyThe Monday Brief — Week of Jul 12, 2026
InMode takeover drama, margin pressure from big brands, and a new player entering the toxin market—what owners need to watch this week.
WeeklyThe Monday Brief: Week of Jul 05, 2026
Galderma's Botox rival stumbles at FDA; Allergan expands with neck approval; InMode faces takeover drama; and the market signals what's working.
WeeklyThe Monday Brief — Week of Jun 28, 2026
Skinvive expands, Allergan signals margin pressure, InMode in play, and the GLP-1 side-effect story deepens—what owners need to watch.
MonthlyMonthly Regulatory Roundup — July 2026
Seven new FDA clearances reshape the aesthetic device landscape. Here's what you need to know to stay compliant.
MonthlyMonthly Regulatory Roundup — June 2026
Twelve new device clearances, a critical compounding recall, and the FDA's formal dermal filler review process kicks off. Here's what you need to know and do.
QuarterlyQuarterly Device Clearance Digest — Q3 2026
LED masks dominate FDA approvals this quarter, while major device makers signal stability. What's actually worth your practice's capital budget.
QuarterlyQuarterly Device Clearance Digest — Q2 2026
Sixteen FDA 510(k) clearances, three major vendor signals, and a clinical trial landscape shift shape the aesthetic device market this quarter.
QuarterlyQuarterly Pricing Pulse — Q3 2026
AbbVie signals, Evolus aggression, and the GLP-1 shadow reshape injectable and filler margins this quarter.
QuarterlyQuarterly Pricing Pulse — Q2 2026
Botox/Juvéderm rebate wars, Jeuveau aggression, and GLP-1 margin squeeze reshape injectable economics—here's what moved and how to protect your bottom line.
AnnualYear in Aesthetics — 2026
AbbVie's loyalty wars, Evolus's ascent, GLP-1 demand surge, and a landmark M&A offer reshape the medspa landscape.